

Guido Grandi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2262263/publications.pdf>

Version: 2024-02-01

69
papers

11,857
citations

81900

39
h-index

102487

66
g-index

72
all docs

72
docs citations

72
times ranked

11046
citing authors

#	ARTICLE	IF	CITATIONS
1	Proteome-minimized outer membrane vesicles from <i>Escherichia coli</i> as a generalized vaccine platform. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12066.	12.2	24
2	Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis. <i>JCI Insight</i> , 2021, 6, .	5.0	7
3	Multi-Antigen Outer Membrane Vesicle Engineering to Develop Polyvalent Vaccines: The <i>Staphylococcus aureus</i> Case. <i>Frontiers in Immunology</i> , 2021, 12, 752168.	4.8	12
4	Commensal <i>Bifidobacterium</i> Strains Enhance the Efficacy of Neo-Epitope Based Cancer Vaccines. <i>Vaccines</i> , 2021, 9, 1356.	4.4	10
5	Structure, dynamics and immunogenicity of a catalytically inactive CXC chemokine-degrading protease SpyCEP from <i>Streptococcus pyogenes</i> . <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 650-660.	4.1	19
6	Bacterial outer membrane vesicles engineered with lipidated antigens as a platform for <i>Staphylococcus aureus</i> vaccine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 21780-21788.	7.1	66
7	Protective effect of Group B <i>Streptococcus</i> type-III polysaccharide conjugates against maternal colonization, ascending infection and neonatal transmission in rodent models. <i>Scientific Reports</i> , 2018, 8, 2593.	3.3	18
8	Vaccination With a FAT1-Derived B Cell Epitope Combined With Tumor-Specific B and T Cell Epitopes Elicits Additive Protection in Cancer Mouse Models. <i>Frontiers in Oncology</i> , 2018, 8, 481.	2.8	18
9	Whole-genome epidemiology, characterisation, and phylogenetic reconstruction of <i>Staphylococcus aureus</i> strains in a paediatric hospital. <i>Genome Medicine</i> , 2018, 10, 82.	8.2	54
10	Functional activity of maternal and cord antibodies elicited by an investigational group B <i>Streptococcus</i> trivalent glycoconjugate vaccine in pregnant women. <i>Journal of Infection</i> , 2018, 76, 449-456.	3.3	22
11	Multiple Stepwise Gene Knockout Using CRISPR/Cas9 in <i>Escherichia coli</i> . <i>Bio-protocol</i> , 2018, 8, e2688.	0.4	3
12	Some Gram-negative Lipoproteins Keep Their Surface Topology When Transplanted from One Species to Another and Deliver Foreign Polypeptides to the Bacterial Surface. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 1348-1364.	3.8	29
13	Large scale validation of an efficient CRISPR/Cas-based multi gene editing protocol in <i>Escherichia coli</i> . <i>Microbial Cell Factories</i> , 2017, 16, 68.	4.0	64
14	Synergistic Protective Activity of Tumor-Specific Epitopes Engineered in Bacterial Outer Membrane Vesicles. <i>Frontiers in Oncology</i> , 2017, 7, 253.	2.8	50
15	TCTN2: a novel tumor marker with oncogenic properties. <i>Oncotarget</i> , 2017, 8, 95256-95269.	1.8	9
16	ERMP1, a novel potential oncogene involved in UPR and oxidative stress defense, is highly expressed in human cancer. <i>Oncotarget</i> , 2016, 7, 63596-63610.	1.8	20
17	Auto-Assembling Detoxified <i>Staphylococcus aureus</i> Alpha-Hemolysin Mimicking the Wild-Type Cytolytic Toxin. <i>Vaccine Journal</i> , 2016, 23, 442-450.	3.1	17
18	The Protective Value of Maternal Group B <i>Streptococcus</i> Antibodies: Quantitative and Functional Analysis of Naturally Acquired Responses to Capsular Polysaccharides and Pilus Proteins in European Maternal Sera. <i>Clinical Infectious Diseases</i> , 2016, 63, 746-753.	5.8	53

#	ARTICLE	IF	CITATIONS
19	FAT1: a potential target for monoclonal antibody therapy in colon cancer. <i>British Journal of Cancer</i> , 2016, 115, 40-51.	6.4	25
20	Vaccinology: The art of putting together the right ingredients. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1311-1317.	3.3	6
21	Protectome Analysis: A New Selective Bioinformatics Tool for Bacterial Vaccine Candidate Discovery. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 418-429.	3.8	25
22	Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against <i>Staphylococcus aureus</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 3680-3685.	7.1	166
23	<i>Streptococcus agalactiae</i> Capsule Polymer Length and Attachment Is Determined by the Proteins CpsABCD. <i>Journal of Biological Chemistry</i> , 2015, 290, 9521-9532.	3.4	45
24	SpyAD, a Moonlighting Protein of Group A <i>Streptococcus</i> Contributing to Bacterial Division and Host Cell Adhesion. <i>Infection and Immunity</i> , 2014, 82, 2890-2901.	2.2	20
25	Analysis of Two-Component Systems in Group B <i>Streptococcus</i> Shows That RgfAC and the Novel FspSR Modulate Virulence and Bacterial Fitness. <i>MBio</i> , 2014, 5, e00870-14.	4.1	67
26	Angiopoietin-like 7, a novel pro-angiogenic factor over-expressed in cancer. <i>Angiogenesis</i> , 2014, 17, 881-896.	7.2	55
27	Antibody-mediated immunity induced by engineered <i>Escherichia coli</i> OMVs carrying heterologous antigens in their lumen. <i>Journal of Extracellular Vesicles</i> , 2014, 3, .	12.2	97
28	Recombinant outer membrane vesicles carrying <i>Chlamydia muridarum</i> HtrA induce antibodies that neutralize chlamydial infection in vitro. <i>Journal of Extracellular Vesicles</i> , 2013, 2, .	12.2	86
29	Multi High-Throughput Approach for Highly Selective Identification of Vaccine Candidates: the Group A <i>Streptococcus</i> Case. <i>Molecular and Cellular Proteomics</i> , 2012, 11, M111.015693.	3.8	115
30	Finding Protective Bacterial Antigens. , 2012, , 27-44.		1
31	Surface Interactome in <i>Streptococcus pyogenes</i> . <i>Molecular and Cellular Proteomics</i> , 2012, 11, M111.015206.	3.8	9
32	A new flow-cytometry-based opsonophagocytosis assay for the rapid measurement of functional antibody levels against Group B <i>Streptococcus</i> . <i>Journal of Immunological Methods</i> , 2012, 378, 11-19.	1.4	22
33	Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of <i>Chlamydia trachomatis</i> vaccines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 9969-9974.	7.1	80
34	A novel polyclonal antibody library for expression profiling of poorly characterized, membrane and secreted human proteins. <i>Journal of Proteomics</i> , 2011, 75, 532-547.	2.4	11
35	Environmental Acidification Drives <i>S. pyogenes</i> Pilus Expression and Microcolony Formation on Epithelial Cells in a FCT-Dependent Manner. <i>PLoS ONE</i> , 2010, 5, e13864.	2.5	47
36	Bacterial vaccine discovery: From "brute force" to high selectivity. <i>Hum Vaccin</i> , 2010, 6, 872-875.	2.4	1

#	ARTICLE	IF	CITATIONS
37	Bacterial surface proteins and vaccines. F1000 Biology Reports, 2010, 2, .	4.0	41
38	CsrRS Regulates Group B <i>Streptococcus</i> Virulence Gene Expression in Response to Environmental pH: a New Perspective on Vaccine Development. Journal of Bacteriology, 2009, 191, 5387-5397.	2.2	88
39	BibA Induces Opsonizing Antibodies Conferring In Vivo Protection against Group B <i>Streptococcus</i> . Journal of Infectious Diseases, 2009, 200, 564-570.	4.0	41
40	Preventing Bacterial Infections with Pilus-Based Vaccines: the Group B <i>Streptococcus</i> Paradigm. Journal of Infectious Diseases, 2009, 199, 108-115.	4.0	201
41	Surfome Analysis as a Fast Track to Vaccine Discovery. Molecular and Cellular Proteomics, 2009, 8, 1728-1737.	3.8	90
42	Proteomics Characterization of Outer Membrane Vesicles from the Extraintestinal Pathogenic <i>Escherichia coli</i> I ⁸⁷ toIR IHE3034 Mutant. Molecular and Cellular Proteomics, 2008, 7, 473-485.	3.8	115
43	Pilus Backbone Contributes to Group B <i>Streptococcus</i> Paracellular Translocation through Epithelial Cells. Journal of Infectious Diseases, 2008, 198, 890-898.	4.0	58
44	BibA: a novel immunogenic bacterial adhesin contributing to group B <i>Streptococcus</i> survival in human blood. Molecular Microbiology, 2007, 63, 754-67.	2.5	87
45	Mg ²⁺ signalling defines the group A streptococcal CsrRS (CovRS) regulon. Molecular Microbiology, 2007, 65, 671-683.	2.5	71
46	Outer membrane vesicles from group B <i>Neisseria meningitidis</i> gna33 mutant: Proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics, 2006, 6, 1856-1866.	2.2	151
47	Identification of novel genomic islands coding for antigenic pilus-like structures in <i>Streptococcus agalactiae</i> . Molecular Microbiology, 2006, 61, 126-141.	2.5	190
48	Characterization and identification of vaccine candidate proteins through analysis of the group A <i>Streptococcus</i> surface proteome. Nature Biotechnology, 2006, 24, 191-197.	17.5	407
49	Group B <i>Streptococcus</i> : global incidence and vaccine development. Nature Reviews Microbiology, 2006, 4, 932-942.	28.6	272
50	Genome Analysis Reveals Pili in Group B <i>Streptococcus</i> . Science, 2005, 309, 105-105.	12.6	278
51	Genome analysis of multiple pathogenic isolates of <i>Streptococcus agalactiae</i> : Implications for the microbial "pan-genome". Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13950-13955.	7.1	2,161
52	Identification of a Universal Group B <i>Streptococcus</i> Vaccine by Multiple Genome Screen. Science, 2005, 309, 148-150.	12.6	497
53	Group A <i>Streptococcus</i> produce pilus-like structures containing protective antigens and Lancefield T antigens. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15641-15646.	7.1	329
54	Genomics and Proteomics in Reverse Vaccines. Methods of Biochemical Analysis, 2005, 49, 379-393.	0.2	22

#	ARTICLE	IF	CITATIONS
55	Identification of new potential vaccine candidates against <i>Chlamydia pneumoniae</i> by multiple screenings. <i>Vaccine</i> , 2005, 23, 1178-1188.	3.8	44
56	GNA33 of <i>Neisseria meningitidis</i> Is a Lipoprotein Required for Cell Separation, Membrane Architecture, and Virulence. <i>Infection and Immunity</i> , 2004, 72, 1914-1919.	2.2	51
57	Genomic Approach for Analysis of Surface Proteins in <i>Chlamydia pneumoniae</i> . <i>Infection and Immunity</i> , 2002, 70, 368-379.	2.2	209
58	Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V <i>Streptococcus agalactiae</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 12391-12396.	7.1	447
59	GNA33 from <i>Neisseria meningitidis</i> serogroup B encodes a membrane-bound lytic transglycosylase (MltA). <i>FEBS Journal</i> , 2002, 269, 3722-3731.	0.2	37
60	Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. <i>Nature Biotechnology</i> , 2002, 20, 914-921.	17.5	205
61	Antibacterial vaccine design using genomics and proteomics. <i>Trends in Biotechnology</i> , 2001, 19, 181-188.	9.3	106
62	Evaluation of Hepatitis C Virus Glycoprotein E2 for Vaccine Design: an Endoplasmic Reticulum-Retained Recombinant Protein Is Superior to Secreted Recombinant Protein and DNA-Based Vaccine Candidates. <i>Journal of Virology</i> , 2000, 74, 6885-6892.	3.4	70
63	Complete Genome Sequence of <i>Neisseria meningitidis</i> Serogroup B Strain MC58. <i>Science</i> , 2000, 287, 1809-1815.	12.6	1,083
64	Identification of Vaccine Candidates Against Serogroup B Meningococcus by Whole-Genome Sequencing. <i>Science</i> , 2000, 287, 1816-1820.	12.6	1,258
65	Binding of Hepatitis C Virus to CD81. <i>Science</i> , 1998, 282, 938-941.	12.6	1,814
66	Coordinate Transcription and Physical Linkage of Domains in Surfactin Synthetase Are Not Essential for Proper Assembly and Activity of the Multienzyme Complex. <i>Journal of Biological Chemistry</i> , 1998, 273, 14403-14410.	3.4	30
67	A new human growth hormone production process using a recombinant <i>Bacillus subtilis</i> strain. <i>Journal of Biotechnology</i> , 1991, 18, 41-54.	3.8	20
68	In Vitro Transcription and Translation Coupled to Two-Dimensional Electrophoresis for Bacterial Proteome Analysis. , 0, , 183-210.		0
69	Outer Membrane Vesicles From The Gut Microbiome Contribute to Tumor Immunity by Eliciting Cross-Reactive T Cells. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	8